Prognosis of Patients With Compete Left Bundle Branch Block

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Mar 25, 2017

Keywords

ClinConnect Summary

This clinical trial is studying patients who have a condition called complete left bundle branch block (CLBBB), which can affect how the heart functions and may lead to heart failure. The researchers want to better understand how this condition impacts the heart's shape and performance, as well as identify which patients might benefit from a treatment called cardiac resynchronization therapy. This is important because more doctors are recognizing that CLBBB can cause problems with the heart working together properly.

To participate in the trial, you need to be at least 18 years old and able to give your consent. You should have a complete left bundle branch block with a specific heart measurement and be classified as having mild to moderate heart issues (NYHA class I, II, or III). If you have other heart conditions, like certain types of heart rhythm problems or have recently had heart surgery, you may not be eligible. Participants can expect thorough evaluations, and their experiences may help researchers find better treatment options for people with this heart condition in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject is 18 years or older and able and willing to consent.
• • The patient should present a complete left bundle branch block (LBBB) with QRS duration of \>120ms
• • The patients should be in NYHA functional class I, II or III.
• Exclusion Criteria:
• • No informed consent
• • Permanent atrial fibrillation, flutter or tachycardia (\>100 bpm).
• • Right bundle branch block
• • Recent myocardial infarction, within 40 days prior to enrolment.
• • Subject underwent coronary artery bypass graft (CABG) or valve surgery, within 90 days.
• • Implanted with a LV assist device (LVAD), or has reasonable probability (per investigator's discretion) of receiving a LVAD in the next year.
• • Severe aortic stenosis (with a valve area of \<1.0 cm2 or significant valve disease expected to be operated on within study period).
• • Complex and uncorrected congenital heart disease.
• • Claustrophobia or devices